Thus, targeting mitochondrial biogenesis and OXPHOS in ER(+) epithelial breast cancer cells may be a new therapeutic strategy for preventing or reversing tamoxifen-resistance in breast cancer patients. This evidence concerns the gene ESR1 and breast carcinoma.